Julie Zhen Qin Wu

Array ( [id] => 10435847 [patent_doc_number] => 20150320859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/556774 [patent_app_country] => US [patent_app_date] => 2014-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 20683 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14556774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551265 [patent_doc_number] => 10344075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Engineered high-affinity human t cell receptors [patent_app_type] => utility [patent_app_number] => 15/037485 [patent_app_country] => US [patent_app_date] => 2014-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 23100 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15037485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10437140 [patent_doc_number] => 20150322153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE' [patent_app_type] => utility [patent_app_number] => 14/538072 [patent_app_country] => US [patent_app_date] => 2014-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 66037 [patent_no_of_claims] => 129 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14538072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083831 [patent_doc_number] => 20160280796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'ANTI-WT1/HLA BI-SPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/034782 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 23608 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15034782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240452 [patent_doc_number] => 20150125447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS' [patent_app_type] => utility [patent_app_number] => 14/533136 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11170 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14533136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053387 [patent_doc_number] => 20160250349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'A NOVEL STABLE FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/030917 [patent_app_country] => US [patent_app_date] => 2014-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7700 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15030917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311724 [patent_doc_number] => 20160347834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Anti-Podoplanin Antibody' [patent_app_type] => utility [patent_app_number] => 14/914704 [patent_app_country] => US [patent_app_date] => 2014-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 29796 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14914704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233259 [patent_doc_number] => 20150118253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE USING ALPHA(2) MACROGLOBULIN-ANTIGENIC MOLECULE COMPLEXES' [patent_app_type] => utility [patent_app_number] => 14/498419 [patent_app_country] => US [patent_app_date] => 2014-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28398 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14498419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536930 [patent_doc_number] => 09611328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Active protease-resistant antibody FC mutants' [patent_app_type] => utility [patent_app_number] => 14/492250 [patent_app_country] => US [patent_app_date] => 2014-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 18034 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14492250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14596895 [patent_doc_number] => 10351631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies [patent_app_type] => utility [patent_app_number] => 14/916166 [patent_app_country] => US [patent_app_date] => 2014-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 16701 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14916166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10248642 [patent_doc_number] => 20150133638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-14 [patent_title] => 'SINGLE-CHAIN ANTIBODIES AND OTHER HETEROMULTIMERS' [patent_app_type] => utility [patent_app_number] => 14/455189 [patent_app_country] => US [patent_app_date] => 2014-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 32402 [patent_no_of_claims] => 120 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14455189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10692373 [patent_doc_number] => 20160038519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES' [patent_app_type] => utility [patent_app_number] => 14/455847 [patent_app_country] => US [patent_app_date] => 2014-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 33093 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14455847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9865388 [patent_doc_number] => 20150045407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'MTK1-ACTIN INHIBITORS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/453497 [patent_app_country] => US [patent_app_date] => 2014-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15222 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14453497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10290705 [patent_doc_number] => 20150175704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'ANTI-NR10 ANTIBODY AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/340883 [patent_app_country] => US [patent_app_date] => 2014-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 37900 [patent_no_of_claims] => 158 [patent_no_of_ind_claims] => 93 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14340883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11642424 [patent_doc_number] => 09663782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-30 [patent_title] => 'Methods and compositions for producing double allele knock outs' [patent_app_type] => utility [patent_app_number] => 14/335903 [patent_app_country] => US [patent_app_date] => 2014-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 12513 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14335903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15850617 [patent_doc_number] => 10640574 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Humanized antibodies with ultralong complementary determining regions [patent_app_type] => utility [patent_app_number] => 14/905765 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 113 [patent_figures_cnt] => 26 [patent_no_of_words] => 92096 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 279 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14905765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9793243 [patent_doc_number] => 20150005187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => 'Biomarkers of Cancer' [patent_app_type] => utility [patent_app_number] => 14/333053 [patent_app_country] => US [patent_app_date] => 2014-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9755 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14333053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11212022 [patent_doc_number] => 09441049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Antibodies reactive with B7-H3 and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/331876 [patent_app_country] => US [patent_app_date] => 2014-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 85 [patent_no_of_words] => 51445 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14331876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10939437 [patent_doc_number] => 20140342457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'RNA-Guided Human Genome Engineering' [patent_app_type] => utility [patent_app_number] => 14/319171 [patent_app_country] => US [patent_app_date] => 2014-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 9870 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14319171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10535102 [patent_doc_number] => 09260723 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-16 [patent_title] => 'RNA-guided human genome engineering' [patent_app_type] => utility [patent_app_number] => 14/319255 [patent_app_country] => US [patent_app_date] => 2014-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 54 [patent_no_of_words] => 10054 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14319255 [rel_patent_id] =>[rel_patent_doc_number] =>)